Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures
Assassi S, Wang X, Chen G, Goldmuntz E, Keyes-Elstein L, Ying J, Wallace PK, Turner J, Zheng WJ, Pascual V, Varga J, Hinchcliff ME, Bellocchi C, McSweeney P, Furst DE, Nash RA, Crofford LJ, Welch B, Pinckney A, Mayes MD, Sullivan KM. Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. Annals Of The Rheumatic Diseases 2019, 78: 1371-1378. PMID: 31391177, PMCID: PMC7167108, DOI: 10.1136/annrheumdis-2019-215770.Peer-Reviewed Original ResearchMeSH KeywordsAdultCyclophosphamideDown-RegulationFemaleHematopoietic Stem Cell TransplantationHumansInterferonsMaleMiddle AgedMultilevel AnalysisMyeloablative AgonistsNeutrophilsRandomized Controlled Trials as TopicScleroderma, SystemicTranscriptomeTransplantation ConditioningTransplantation, AutologousTreatment OutcomeUp-RegulationConceptsHaematopoietic stem cell transplantationStem cell transplantationSystemic sclerosisNeutrophil modulesCell transplantationAutologous stem cell transplantationMolecular signaturesImproved clinical outcomesSerum protein levelsDisease-related molecular signaturesCYC armMonths postrandomisationBaseline visitSkin scoreClinical outcomesCyclophosphamide treatmentVital capacityPretreatment baselineSignificant changesControl armBlood transcriptsWhole blood transcriptsConventional treatmentInterferonBaseline samples
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply